CN107875201A - 一种降尿酸干预肾脏病及尿毒症的沙棘复方制剂及制备方法 - Google Patents
一种降尿酸干预肾脏病及尿毒症的沙棘复方制剂及制备方法 Download PDFInfo
- Publication number
- CN107875201A CN107875201A CN201711209785.3A CN201711209785A CN107875201A CN 107875201 A CN107875201 A CN 107875201A CN 201711209785 A CN201711209785 A CN 201711209785A CN 107875201 A CN107875201 A CN 107875201A
- Authority
- CN
- China
- Prior art keywords
- sea
- buckthorn
- hour
- extract solution
- mesh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003145 Hippophae rhamnoides Nutrition 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 title claims abstract description 22
- 210000003734 kidney Anatomy 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 240000000950 Hippophae rhamnoides Species 0.000 title abstract 3
- 241000229143 Hippophae Species 0.000 claims abstract description 72
- 238000000605 extraction Methods 0.000 claims abstract description 31
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 20
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 20
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 19
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 19
- 229940067866 dandelion extract Drugs 0.000 claims abstract description 10
- 235000020691 dandelion extract Nutrition 0.000 claims abstract description 10
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 235000005911 diet Nutrition 0.000 claims abstract description 8
- 230000000378 dietary effect Effects 0.000 claims abstract description 8
- 239000000706 filtrate Substances 0.000 claims description 32
- 230000001954 sterilising effect Effects 0.000 claims description 30
- 235000003935 Hippophae Nutrition 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 21
- 238000007906 compression Methods 0.000 claims description 20
- 238000001704 evaporation Methods 0.000 claims description 20
- 230000008020 evaporation Effects 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 18
- 238000004659 sterilization and disinfection Methods 0.000 claims description 18
- 239000012141 concentrate Substances 0.000 claims description 17
- 235000008504 concentrate Nutrition 0.000 claims description 17
- 239000000047 product Substances 0.000 claims description 15
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 9
- 241000245665 Taraxacum Species 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 3
- 240000001949 Taraxacum officinale Species 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 5
- 208000037157 Azotemia Diseases 0.000 abstract description 4
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 208000009852 uremia Diseases 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 208000020832 chronic kidney disease Diseases 0.000 description 8
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000002019 anti-mutation Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- FRWNAQDBODEVAL-VMPITWQZSA-N (5e)-5-[(4-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\1C(=O)NC(=S)S/1 FRWNAQDBODEVAL-VMPITWQZSA-N 0.000 description 1
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 description 1
- HHXYJYBYNZMZKX-UHFFFAOYSA-N 3,4:15,16-diepoxy-7-oxo-13(16),14-clerodadien-20,12-olide-(3alpha,4alpha)-form Natural products C12CCC3C4(C)CCCC(C)(C)C4CCC3(C)C1(C)CCC1C2(C)CCC1C(=C)C HHXYJYBYNZMZKX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000219051 Fagopyrum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种降尿酸、干预肾脏病及尿毒症的沙棘复方制剂及制备方法，属于食疗食品、保健品及准字药制备领域。该药食两用品种组合物重量份数组成为：沙棘浓缩浆35‑70，沙棘叶提取液10‑30，蒲公英提取液10‑30，余甘子提取液8‑30，苦荞麦提取液7‑30。上述组合物的制备方法是常温闪式提取、低温(50℃以下)浓缩，最大限度保留生物活性成分。本发明组成物全为药食两用品种，安全、可以长期服用。本发明产品能有效降尿酸、有效干预慢性肾脏病及尿毒症。为国民有效预防高尿酸血症发生，预防慢性肾脏病发生提供了安全、有效产品。
Description
技术领域：
本发明涉及机体降低尿酸、干预慢性肾脏病及尿毒症，为其而专门研制药食两用品种沙棘鲜浆、沙棘叶提取液、蒲公英提取液、余甘子提取液、苦荞麦提取液配伍制成的食疗产品沙棘复方口服液。
背景技术：
目前，保守估计，全国高尿酸血症患者已突破1.2亿，其中痛风患者超过7500万人。高尿酸已成为继高血压、高血糖、高血脂(三高)之后的第四高。我国慢性肾脏病患者也突破1.2亿，是又一威胁国民健康的重要疾病，成为重要公共卫生问题。据统计，中国大约有100多万名尿毒症患者，并以每年12万人的速度递增。
治疗高尿酸的药物主要是一些排尿酸的药物，主要是苯磺唑酮、羧苯磺胺等，这些西药都有严重的毒副作用，而且只能治标，无法治愈！治疗慢性肾病的他汀类药物不仅有严重的毒副作用，而且只能延缓慢性肾脏病的进展。中医系统干预综合治疗慢性肾脏病也没有明显的效果！尿毒症的治疗也只能是透析来勉强维持生命！
以药食两用品种沙棘鲜浆、沙棘叶提取液、蒲公英提取液、余甘子提取液、苦荞麦提取液配伍制成的沙棘复方口服液降尿酸、干预慢性肾脏病及尿毒症产品尚属空白。
本发明的目的，在于提供一种降低尿酸、干预慢性肾脏病及尿毒症的沙棘复方口服液产品及其制作方法。
本发明的技术方案如下：
本发明药食两用品种食疗产品“沙棘复方口服液”是由：沙棘鲜浆、沙棘叶、蒲公英、余甘子、苦荞麦组成。
本发明降尿酸、干预慢性肾脏病及尿毒症的药食两用食疗产品“沙棘复方口服液”由以下重量份数的药食两用品种组成：沙棘浓缩浆35-70，沙棘叶提取液10-30，蒲公英提取液10-30，余甘子提取液8-30，苦荞麦提取液7-30。
本发明配方中的沙棘浓缩浆主要含有多种维生素、氨基酸、蛋白质、胡萝卜素、类胡萝卜素、有机酸、多糖类、黄酮类、脂肪酸、甾醇类、三萜类及多种必要微量元素等多种活性物质。现代药理学研究证实，沙棘浓缩浆具有增强免疫力、抗氧化、抗炎、抗突变、降血脂、降血粘、降血糖、抗心律失常、抗凝血、抑制血小板聚集、抗缺血、抗辐射、脑缺血保护、解重金属毒、保护肝脏、预防癌症等广泛的保健药理作用。沙棘叶主要含有多种维生素、蛋白质、氨基酸、胡萝卜素、类胡萝卜素、多糖类、黄酮类、SOD、多酚类、科罗索酸及多种微量元素等多种活性物质。沙棘叶提取物具有增强免疫力、抗氧化、抗突变、降血脂、降血糖、抗心律失常、抗凝血、抗心肌缺血、抑制血小板聚集、脑缺血保护、抗炎、抗辐射、解重金属毒、保护肝脏、抗肝硬化、消除亚硝酸盐、预防癌症等广泛的保健药理作用。蒲公英富含多种维生素、胡萝卜素、类胡萝卜素、多糖类、黄酮类、甾醇类、有机酸、胆碱、蒲公英醇、蒲公英素、蒲公英苦素及多种微量元素等多种活性成分。现代药理学证实，蒲公英活性成分具有增强免疫力、抗突变、抗炎抑菌、降血脂、降血糖、保护肝脏、抗胃溃疡、增强胃肠动力、润肠通便、解食毒等广泛的保健药理作用。余甘子提取物富含多种维生素、多种氨基酸、有机酸、蛋白质、多糖类、黄酮类、SOD、生物碱、单宁、鞣质、矿物质及多种必要的微量元素等活性成分。现代药理学证实，余甘子提取物具有增强免疫力、抗氧化、抗菌抗炎、降血脂、降血压、降血糖、抗衰老、抗癌、保肝肾、、解重金属毒等广泛的保健药理作用。苦荞麦富含多种维生素、蛋白质、纤维素、生物类黄酮、富含钙、磷、钾、铁、铜、锌、镁、锰、硒等多种矿物质及微量元素。具有降血脂、降血压、降血糖、软化血管、特别是苦荞中含有其它谷类作物缺乏的硒，硒在人体内与金属相结合形成一种不稳定的“金属-硒-蛋白”复合物，有助于排解人体中的有毒物质(如铅、汞、镐等毒素)。本方五味合用，形成活性成分群，其共同叠加效应起到更有效的降尿酸、干预慢性肾脏病及尿毒症的作用。特别是该产品能有效降尿酸而预防高尿酸血症的发生，预防慢性肾脏病的发生。
本发明所述降尿酸、干预慢性肾脏病及尿毒症的药食两用品种“沙棘复方口服液”制备方法，步骤如下：
1、按比例称取各品种；
2、制备沙棘浓缩浆：将超高温瞬时灭菌后的沙棘鲜浆，采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩至固形物大于18％的沙棘浓缩浆；
3、制备沙棘叶提取液：沙棘叶破碎至10-40目；10-20倍纯水浸泡1小时以上；15-50℃常温闪式提取法提取0.2～0.5小时，提取2次，300目过滤；滤液高温瞬时灭菌；灭菌滤液采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液；
4、制备蒲公英提取液：沙棘叶破碎至10-40目；10-20倍纯水浸泡1小时以上；15-50℃常温闪式提取法提取0.2～0.5小时，提取2次，300目过滤；滤液高温瞬时灭菌；灭菌滤液采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液；
5、制备余甘子提取液：沙棘叶破碎至10-40目；10-20倍纯水浸泡1小时以上；15-50℃常温闪式提取法提取0.2～0.5小时，提取2次，300目过滤；滤液高温瞬时灭菌；灭菌滤液采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液；
6、制备苦荞麦提取液：沙棘叶破碎至10-40目；10-20倍纯水浸泡1小时以上；15-50℃常温闪式提取法提取0.2～0.5小时，提取2次，300目过滤；滤液高温瞬时灭菌；灭菌滤液采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液；
7、沙棘复方口服液制备：将沙棘浓缩浆、沙棘叶提取液、蒲公英提取液、余甘子提取液、苦荞麦提取液混合均匀，制成降尿酸、干预肾脏病及尿毒症的食疗产品“沙棘复方口服液”，也可制成浓缩丸、颗粒剂、粉剂。
本发明的有益结果：
1、本发明配方全为药食两用品种，确保了产品的安全性，可以长期服用，无毒副作用。
2、本发明“沙棘复方口服液”不仅能降尿酸、有效干预肾脏病及尿毒症加重，而且能有效预防高尿酸血症的发生，预防肾脏病的发生。
3、本发明“沙棘复方口服液”产品制备方法采用了高新技术常温闪式提取技术，低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩技术，提取，浓缩温度低、时间短、不仅大大提高了产品的生物活性，而且节能环保，大大降低了生产成本。
具体实施方式：
实施例1：
(1)、按比例称取各品种：沙棘浓缩浆240公斤，沙棘叶35公斤，蒲公英33公斤，余甘子22公斤，苦荞麦20公斤。
(2)制备沙棘叶提取液：将35公斤沙棘叶破碎至20-40目；用20倍纯水浸泡1小时以上；40℃闪式提取法提取0.3小时，过滤；滤渣加10倍纯水，40℃闪式提取0.2小时，过滤；合并两次滤液，超高温瞬时灭菌；灭菌滤液45℃负压(-0.095MPa)热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液50公斤；
(3)制备蒲公英提取液：将33公斤沙棘叶破碎至20-40目；用20倍纯水浸泡1小时以上；40℃闪式提取法提取0.3小时，过滤；滤渣加10倍纯水，40℃闪式提取0.2小时，过滤；合并两次滤液，超高温瞬时灭菌；灭菌滤液45℃负压(-0.095MPa)热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液45公斤；
(4)制备余甘子提取液：将22公斤沙棘叶破碎至20-40目；用20倍纯水浸泡1小时以上；40℃闪式提取法提取0.3小时，过滤；滤渣加10倍纯水，40℃闪式提取0.2小时，过滤；合并两次滤液，超高温瞬时灭菌；灭菌滤液45℃负压(-0.095MPa)热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液35公斤；
(5)制备苦荞麦提取液：将20公斤沙棘叶破碎至20-40目；用20倍纯水浸泡1小时以上；40℃闪式提取法提取0.3小时，过滤；滤渣加10倍纯水，40℃闪式提取0.2小时，过滤；合并两次滤液，超高温瞬时灭菌；灭菌滤液45℃负压(-0.095MPa)热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液30公斤；
(6)沙棘复方口服液制备：将沙棘浓缩浆240公斤、沙棘叶提取液50公斤、蒲公英提取液45公斤、余甘子提取液35公斤、苦荞麦提取液30公斤混合均匀，罐装50毫升的口服液，理论产量8000支。检验，成品。待用。制成降尿酸、干预肾脏病及尿毒症的食疗产品“沙棘复方口服液”。
(7)服用剂量及方法：
每次1支，每日2次。
实施例2：
(1)按比例称取各品种：沙棘浓缩浆500公斤，沙棘叶80公斤，蒲公英78公斤，余甘子70公斤，苦荞麦65公斤。
(2)制备沙棘叶提取液：将80公斤沙棘叶破碎至20-40目；用20倍纯水浸泡1小时以上；40℃闪式提取法提取0.3小时，过滤；滤渣加10倍纯水，40℃闪式提取0.2小时，过滤；合并两次滤液，超高温瞬时灭菌；灭菌滤液45℃负压(-0.095MPa)热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液130公斤；
(3)制备蒲公英提取液：将78公斤沙棘叶破碎至20-40目；用20倍纯水浸泡1小时以上；40℃闪式提取法提取0.3小时，过滤；滤渣加10倍纯水，40℃闪式提取0.2小时，过滤；合并两次滤液，超高温瞬时灭菌；灭菌滤液45℃负压(-0.095MPa)热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液128公斤；
(4)制备余甘子提取液：将70公斤沙棘叶破碎至20-40目；用20倍纯水浸泡1小时以上；40℃闪式提取法提取0.3小时，过滤；滤渣加10倍纯水，40℃闪式提取0.2小时，过滤；合并两次滤液，超高温瞬时灭菌；灭菌滤液45℃负压(-0.095MPa)热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液122公斤；
(5)制备苦荞麦提取液：将65公斤沙棘叶破碎至20-40目；用20倍纯水浸泡1小时以上；40℃闪式提取法提取0.3小时，过滤；滤渣加10倍纯水，40℃闪式提取0.2小时，过滤；合并两次滤液，超高温瞬时灭菌；灭菌滤液45℃负压(-0.095MPa)热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液120公斤；
(6)沙棘复方口服液制备：将沙棘浓缩浆500公斤、沙棘叶提取液130公斤、蒲公英提取液128公斤、余甘子提取液122公斤、苦荞麦提取液120公斤混合均匀，罐装50毫升的口服液，理论产量20000支。检验，成品。待用。制成降尿酸、干预肾脏病及尿毒症的食疗产品“沙棘复方口服液”。
(7)服用剂量及方法：
每次1支，每日2次。
Claims (3)
1.一种降尿酸、干预肾脏病及尿毒症的沙棘复方制剂及制备方法，其特征在于由以下品种组成：沙棘鲜浆、沙棘叶、蒲公英、余甘子、苦荞麦，其提取物重量份数组成为：沙棘浓缩浆35-70，沙棘叶提取物10-30，蒲公英提取物10-30，余甘子提取液8-30，苦荞麦提取液7-30；
(1)、制备沙棘浓缩浆：将超高温瞬时灭菌后的沙棘鲜浆，采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩至固形物大于18％的沙棘浓缩浆；
(2)、制备沙棘叶提取液：沙棘叶破碎至10-40目；10-20倍纯水浸泡1小时以上；15-50℃常温闪式提取法提取0.2～0.5小时，提取2次，300目过滤；滤液高温瞬时灭菌；灭菌滤液采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液；
(3)、制备蒲公英提取液：蒲公英破碎至10-40目；10-20倍纯水浸泡1小时以上；15-50℃常温闪式提取法提取0.2～0.5小时，提取2次，300目过滤；滤液高温瞬时灭菌；灭菌滤液采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液；
(4)、制备余甘子提取液：余甘子破碎至10-40目；10-20倍纯水浸泡1小时以上；15-50℃常温闪式提取法提取0.2～0.5小时，提取2次，300目过滤；滤液高温瞬时灭菌；灭菌滤液采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液；
(5)、制备苦荞麦提取液：苦荞麦破碎至10-40目；10-20倍纯水浸泡1小时以上；15-50℃常温闪式提取法提取0.2～0.5小时，提取2次，300目过滤；滤液高温瞬时灭菌；灭菌滤液采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩至固形物大于18％的浓缩液；
(6)、沙棘复方口服液制备：将沙棘浓缩浆、沙棘叶提取液、蒲公英提取液、余甘子提取液、苦荞麦提取液混合均匀，制成降尿酸、干预肾脏病及尿毒症的食疗产品50毫升沙棘复方口服液。
2.根据权利要求1所述降尿酸、干预肾脏病及尿毒症的沙棘复方制剂，其特征在于：生产工艺采取15-50℃常温闪式提取法提取；采用低温(50℃以下)负压(-0.095MPa以上)闭环式热泵蒸发浓缩装置浓缩提取液。
3.根据权利要求1所述降尿酸、干预肾脏病及尿毒症的沙棘复方制剂食疗产品可制成各种剂型，包括浓缩丸、颗粒剂、粉剂等。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711209785.3A CN107875201A (zh) | 2017-11-28 | 2017-11-28 | 一种降尿酸干预肾脏病及尿毒症的沙棘复方制剂及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711209785.3A CN107875201A (zh) | 2017-11-28 | 2017-11-28 | 一种降尿酸干预肾脏病及尿毒症的沙棘复方制剂及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107875201A true CN107875201A (zh) | 2018-04-06 |
Family
ID=61775509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711209785.3A Pending CN107875201A (zh) | 2017-11-28 | 2017-11-28 | 一种降尿酸干预肾脏病及尿毒症的沙棘复方制剂及制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107875201A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109718320A (zh) * | 2019-02-27 | 2019-05-07 | 山东省农业科学院 | 一种降尿酸的功能饮料 |
| CN110003354A (zh) * | 2019-05-08 | 2019-07-12 | 吉林化工学院 | 一种具有抗氧化功能的沙棘多糖闪式制备工艺 |
| CN110037258A (zh) * | 2019-04-15 | 2019-07-23 | 北京宝得瑞健康产业有限公司 | 一种抗突变、抑癌及诱导癌细胞凋亡的沙棘复方超微粉剂及其制法 |
| CN115671219A (zh) * | 2022-11-10 | 2023-02-03 | 山东省科学院新材料研究所 | 一种治疗痛风的中药组合物及其制备方法和应用 |
-
2017
- 2017-11-28 CN CN201711209785.3A patent/CN107875201A/zh active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109718320A (zh) * | 2019-02-27 | 2019-05-07 | 山东省农业科学院 | 一种降尿酸的功能饮料 |
| CN109718320B (zh) * | 2019-02-27 | 2021-10-19 | 山东省农业科学院 | 一种降尿酸的功能饮料 |
| CN110037258A (zh) * | 2019-04-15 | 2019-07-23 | 北京宝得瑞健康产业有限公司 | 一种抗突变、抑癌及诱导癌细胞凋亡的沙棘复方超微粉剂及其制法 |
| CN110003354A (zh) * | 2019-05-08 | 2019-07-12 | 吉林化工学院 | 一种具有抗氧化功能的沙棘多糖闪式制备工艺 |
| CN115671219A (zh) * | 2022-11-10 | 2023-02-03 | 山东省科学院新材料研究所 | 一种治疗痛风的中药组合物及其制备方法和应用 |
| CN115671219B (zh) * | 2022-11-10 | 2024-03-22 | 山东省科学院新材料研究所 | 一种治疗痛风的中药组合物及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107875201A (zh) | 一种降尿酸干预肾脏病及尿毒症的沙棘复方制剂及制备方法 | |
| CN102771607A (zh) | 一种清实火凉茶及其制备方法 | |
| KR101202988B1 (ko) | 건강 약차 및 그 제조방법 | |
| CN105878803B (zh) | 一种具有防治酒精性肝损伤的人参竹叶组合物 | |
| CN101755970A (zh) | 一种降血压保健茶 | |
| KR101080573B1 (ko) | 고장초 추출물을 주성분으로 한 건강 약차 및 그 제조 방법 | |
| CN103566150A (zh) | 一种具有降血脂作用的药食同源食品的组合物及其应用 | |
| CN105981853A (zh) | 一种营养功能丰富的温和的暖茶饮料配方 | |
| KR101080458B1 (ko) | 당귀 추출물이 포함된 액상차 및 그 제조방법 | |
| KR100837140B1 (ko) | 건강음료의 제조방법 및 그에 따른 건강음료 | |
| CN108260682A (zh) | 一种降血糖、降血脂和降血压的保健茶 | |
| RU2580282C1 (ru) | Средство для профилактики и лечения мочекаменной болезни | |
| RU2435450C1 (ru) | Биологически активная добавка к пище origitea® очищение вечер | |
| CN105851352A (zh) | 一种含白茶提取物的有效部位组合物及其制备方法和应用 | |
| CN106620245A (zh) | 一种降低空腹血糖及餐后血糖的沙棘叶五味丸及制备方法 | |
| KR101381277B1 (ko) | 홍삼을 함유하는 고장초 겔 | |
| KR20050080501A (ko) | 고혈압, 비만, 당뇨병환자를 위한 건강보조식품의 제조방법 | |
| RU2321418C1 (ru) | Средство общеукрепляющего и тонизирующего действия и способ его получения | |
| CN104491338B (zh) | 一种润肠通便的药食两用组合物及其制备方法 | |
| KR101490793B1 (ko) | 차 조성물의 제조방법, 및 그로부터 제조된 차 조성물 | |
| RU2442595C2 (ru) | Фитокомплекс для лечения онкологических заболеваний и способ лечения заболеваний желудочно-кишечного тракта с его применением | |
| RU2259839C2 (ru) | Чай "неполнита-фито" из лекарственных растений для снижения избыточного веса | |
| Simons | The Healing Power of Plants: Medical Plants from Abuta and Acerola to Yohimbe and Yucca: a Practical Selection | |
| KR20180046232A (ko) | 오징어뼈 추출물 및 참소리쟁이 추출물을 함유하는 구강 세정용 조성물 | |
| RU2361428C1 (ru) | Оздоровительная биологически активная добавка к пище |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200417 Address after: 101117 Beijing City Lucheng town Tongzhou District City Industrial Zone No. 15 Applicant after: BEIJING POWDERY HEALTH INDUSTRY Co.,Ltd. Applicant after: Zou Wei Address before: 050090 Hebei province Shijiazhuang Qiaoxi District Xinshi North Road, Riverside District (Yixing Shenxing Park) 4 Building 1 unit 202 room Applicant before: Zou Wei |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180406 |